Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Darlene E Mccord operates in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are assigned to 2 distinct examiners, meaning each examiner is managing a pending matter. Despite the involvement of multiple examiners, the portfolio is concentrated within 1 distinct art unit, suggesting a narrow technical focus for these applications. The consolidation of pending office actions into a distinct art unit may allow for a more uniform strategy across the Biotechnology & Pharmaceuticals filings.
The busiest examiner, ZHANG SPIERING, DONGXIU, is currently handling 1 pending office action. With 2 distinct examiners and pending office actions, the prosecution workload is distributed. Practitioners should note that the 1 distinct art unit provides a consistent regulatory framework for the applications. This structure simplifies the management of the portfolio by limiting the number of art units that counsel must navigate. The arrangement ensures that the pending office action handled by the busiest examiner is reviewed within the same technical context as the other matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG SPIERING, DONGXIU | 1 | 45.2% | +70.9% |
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18649065 | COMPOSITIONS AND METHODS OF DISSOLVING BIOFILM TO PROMOTE WOUND HEALING | SHOMER, ISAAC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18984413 | COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF | ZHANG SPIERING, DONGXIU | — |
| 18649065 | COMPOSITIONS AND METHODS OF DISSOLVING BIOFILM TO PROMOTE WOUND HEALING | SHOMER, ISAAC | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18984413 | COATED MEDICINAL CLAY COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, AND DELIVERY OF CATION SOURCES AND METHODS OF USE THEREOF | ZHANG SPIERING, DONGXIU | — | §103§112DP | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18649065 | COMPOSITIONS AND METHODS OF DISSOLVING BIOFILM TO PROMOTE WOUND HEALING | SHOMER, ISAAC | 1612 | §103§112 | Final Rejection | — | Pending | Apr 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial